US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tvardi Therapeutics Inc

24.61

-0.6000-2.38%

Post-market: 24.610.00000.00%17:55 EDT

Volume:515.47K

Turnover:12.68M

Market Cap:230.37M

PE:-1.58

High:25.59

Open:24.82

Low:23.89

Close:25.21

Loading ...

Overview Company News Filings

BUZZ-Tvardi Therapeutics up after Piper Sandler starts coverage

Tvardi Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Target Price $78

THOMSON REUTERS

Tvardi Therapeutics (TVRD) Receives a New Rating from BTIG

Tvardi Therapeutics files to sell 2.08M shares of common stock for holders

Tvardi Therapeutics (TVRD) Gets a Buy from BTIG

BRIEF-Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

Tvardi Therapeutics Inc - Topline Data From Revert Ipf Trial Expected in Q4 2025

THOMSON REUTERS

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO)

Tvardi Therapeutics Initiated at Outperform by Oppenheimer

Oppenheimer Initiates Tvardi Therapeutics at Outperform With $65 Price Target

MT Newswires Live

BUZZ-U.S. STOCKS ON THE MOVE-Xponential Fitness, Phillips 66, Amazon.com

BUZZ-U.S. STOCKS ON THE MOVE-Deere, Lockheed Martin, Alibaba.com

BTIG Initiates Tvardi Therapeutics at Buy With $55 Price Target

MT Newswires Live

BUZZ-BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise

Tvardi Therapeutics Completes Merger with Cara Therapeutics, Secures Funding Through 2026

BRIEF-Tvardi Therapeutics Announces First Quarter 2025 Results And Provides Business Update

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

THOMSON REUTERS

Tvardi Therapeutics Inc - Completes Merger With Cara Therapeutics

THOMSON REUTERS

Tvardi Therapeutics: on Track for Multiple Phase 2 Data Readouts With Stat3 Inhibitor, Tti-101, With Lead Program in Ipf Expected in 2H 2025

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TVRD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":24.61,"timestamp":1751054400000,"preClose":25.21,"halted":0,"volume":515466,"hourTrading":{"tag":"盘后","latestPrice":24.61,"preClose":24.61,"latestTime":"17:55 EDT","volume":154114,"amount":3792718.398296,"timestamp":1751061340345},"delay":0,"floatShares":7933194,"shares":9360904,"eps":-15.531682,"marketStatus":"Market Closed","change":-0.6,"latestTime":"06-27 16:00:00 EDT","open":24.82,"high":25.5921,"low":23.89,"amount":12680242.465086,"amplitude":0.067517,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-15.531682,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":25.21,"preHourTrading":{"tag":"盘前","latestPrice":25.25,"preClose":25.21,"latestTime":"09:29 EDT","volume":15,"amount":378.75,"timestamp":1751030970083},"postHourTrading":{"tag":"盘后","latestPrice":24.61,"preClose":24.61,"latestTime":"17:55 EDT","volume":154114,"amount":3792718.398296,"timestamp":1751061340345},"volumeRatio":3.691154},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","floatShares":7933194,"roa":"--","roe":"--","lyrEps":-15.531682,"volumeRatio":3.691154,"shares":9360904,"dividePrice":0,"high":25.5921,"amplitude":0.067517,"preClose":25.21,"low":23.89,"week52Low":8.1252,"pbRate":"--","week52High":34.31,"institutionHeld":0,"latestPrice":24.61,"eps":-15.531682,"divideRate":0,"volume":515466,"delay":0,"ttmEps":-15.531682,"open":24.82,"prevYearClose":18.36,"prevWeekClose":25.77,"prevMonthClose":28.34,"prevQuarterClose":15.21,"fiveDayClose":25.77,"twentyDayClose":29.86,"sixtyDayClose":14.82},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVRD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2543493895","title":"BUZZ-Tvardi Therapeutics up after Piper Sandler starts coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2543493895","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543493895?lang=en_us&edition=fundamental","pubTime":"2025-06-13 01:01","pubTimestamp":1749747711,"startTime":"0","endTime":"0","summary":"BUZZ-Tvardi Therapeutics up after Piper Sandler starts coverage** Shares of Tvardi Therapeutics TVRD.O rise 4.5% to $27.40** Piper Sandler initiates coverage of TVRD with an \"overweight\" rating and PT of $78 ** Piper believes that TVRD's lead drug, TTI-101, is positioned to drive broad improvement with an optimal profile** TTI-101 is uniquely positioned to drive meaningful anti-fibrotic effects for idiopathic pulmonary fibrosis , a chronic lung disease, at cellular and immune levels - brokerage** TVRD is developing TTI-109 as a next generation STAT3 inhibitor, with investigational new drug application submitted in June 2025 ** TTI-109 offers a significant pipeline opportunity for TVRD with an optimized product profile and extended coverage to ensure sustained use over time - Piper Sandler** TVRD stock up ~43% YTD, as of last close","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nL4N3SF164:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2542359882","title":"Tvardi Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Target Price $78","url":"https://stock-news.laohu8.com/highlight/detail?id=2542359882","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542359882?lang=en_us&edition=fundamental","pubTime":"2025-06-12 15:38","pubTimestamp":1749713919,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nFWN3SF060:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"2540115767","title":"Tvardi Therapeutics (TVRD) Receives a New Rating from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2540115767","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540115767?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:16","pubTimestamp":1748862979,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics (TVRD – Research Report) received a Buy rating and a $55.00 price target from BTIG analyst Julian Harrison today. According to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/tvardi-therapeutics-tvrd-receives-a-new-rating-from-btig-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/tvardi-therapeutics-tvrd-receives-a-new-rating-from-btig-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVRD"],"gpt_icon":0},{"id":"2539427074","title":"Tvardi Therapeutics files to sell 2.08M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2539427074","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539427074?lang=en_us&edition=fundamental","pubTime":"2025-05-31 04:10","pubTimestamp":1748635825,"startTime":"0","endTime":"0","summary":"16:05 EDT Tvardi Therapeutics (TVRD) files to sell 2.08M shares of common stock for holders Published first on TheFly – the ultimate source for rea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tvardi-therapeutics-files-to-sell-2-08m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tvardi-therapeutics-files-to-sell-2-08m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVRD","BK4007","BK4539","BK4139","LENZ"],"gpt_icon":0},{"id":"2538738874","title":"Tvardi Therapeutics (TVRD) Gets a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2538738874","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538738874?lang=en_us&edition=fundamental","pubTime":"2025-05-28 19:35","pubTimestamp":1748432158,"startTime":"0","endTime":"0","summary":"In a report released today, Julian Harrison from BTIG reiterated a Buy rating on Tvardi Therapeutics (TVRD – Research Report), with a price target ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/tvardi-therapeutics-tvrd-gets-a-buy-from-btig?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/tvardi-therapeutics-tvrd-gets-a-buy-from-btig?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"2538461638","title":"BRIEF-Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2538461638","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538461638?lang=en_us&edition=fundamental","pubTime":"2025-05-27 21:06","pubTimestamp":1748351173,"startTime":"0","endTime":"0","summary":"BRIEF-Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary FibrosisMay 27 (Reuters) - Tvardi Therapeutics Inc TVRD.O:TVARDI THERAPEUTICS ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA7YBGNG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2538779465","title":"Tvardi Therapeutics Inc - Topline Data From Revert Ipf Trial Expected in Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2538779465","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538779465?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:00","pubTimestamp":1748347203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA7YBGNG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"2538657984","title":"Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2538657984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538657984?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:00","pubTimestamp":1748347203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA7YBGNG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2537155427","title":"Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2537155427","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537155427?lang=en_us&edition=fundamental","pubTime":"2025-05-24 00:30","pubTimestamp":1748017810,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tvardi Therapeutics (TVRD – Research Report) and ALX...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tvardi-therapeutics-tvrd-and-alx-oncology-holdings-alxo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tvardi-therapeutics-tvrd-and-alx-oncology-holdings-alxo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","BK4007","BK4080","HCSG","ALX","BK4231","TVRD","ALXO"],"gpt_icon":0},{"id":"2537325469","title":"Tvardi Therapeutics Initiated at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2537325469","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537325469?lang=en_us&edition=fundamental","pubTime":"2025-05-21 23:23","pubTimestamp":1747840980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 21, 2025 11:23 ET (15:23 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPY","LENZ","TVRD"],"gpt_icon":0},{"id":"2537874189","title":"Oppenheimer Initiates Tvardi Therapeutics at Outperform With $65 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2537874189","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537874189?lang=en_us&edition=fundamental","pubTime":"2025-05-21 19:37","pubTimestamp":1747827420,"startTime":"0","endTime":"0","summary":"Oppenheimer Initiates Tvardi Therapeutics at Outperform With $65 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","TVRD","LENZ"],"gpt_icon":0},{"id":"2535587167","title":"BUZZ-U.S. STOCKS ON THE MOVE-Xponential Fitness, Phillips 66, Amazon.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2535587167","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535587167?lang=en_us&edition=fundamental","pubTime":"2025-05-16 02:11","pubTimestamp":1747332671,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Xponential Fitness, Phillips 66, Amazon.com Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nL6N3RN0NN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHVN","LMT","AMZN","KVYO","ATRA","TOL","AURA","AKAM","SVV","WAY","USAW.SI","IE00B5TLWC47.USD","LU1291159041.SGD","BOOT","LU1699723380.USD","CSIQ","XOM","LU0052756011.USD","VIRT","LOAR","LU1435385759.SGD","XPOF","LU0072462426.USD","CVS","MOH","BIRK","HUM","LU0157215616.USD","ALL","DLO","ABT","ISRG","TVRD","NFE","LU1732800096.USD","ELV","DE","TTWO","COP","LU0109392836.USD","PSX","CVX"],"gpt_icon":1},{"id":"2535823227","title":"BUZZ-U.S. STOCKS ON THE MOVE-Deere, Lockheed Martin, Alibaba.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2535823227","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535823227?lang=en_us&edition=fundamental","pubTime":"2025-05-15 21:18","pubTimestamp":1747315091,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Deere, Lockheed Martin, Alibaba.com Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nL6N3RN0IZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250843.SGD","BK4588","FL","LU1769817096.USD","CARA","CVX","LU0433182093.SGD","LU1585245621.USD","LOAR","LU1093756325.SGD","LU0612318385.USD","CSIQ","VIRT","LU0368265418.SGD","LU0976567544.SGD","BOOT","LU2226246903.HKD","KVYO","LU0149725797.USD","DE","BK4516","SVV","LU0198837287.USD","09988","XOM","LU0203345920.USD","BIRK","LU1880398471.USD","IE00B7SZLL34.SGD","LU0130102774.USD","AKAM","LU0266512127.USD","BHVN","COP","ALBmain","LU0985320562.USD","BAC","IE00BKDWB100.SGD","LU1035773651.USD","DKS","IE00BJJMRX11.SGD","BABA","WAY","TVRD","LMT"],"gpt_icon":1},{"id":"2535841291","title":"BTIG Initiates Tvardi Therapeutics at Buy With $55 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2535841291","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535841291?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:47","pubTimestamp":1747309659,"startTime":"0","endTime":"0","summary":"BTIG Initiates Tvardi Therapeutics at Buy With $55 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","TVRD"],"gpt_icon":0},{"id":"2535846417","title":"BUZZ-BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise","url":"https://stock-news.laohu8.com/highlight/detail?id=2535846417","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535846417?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:18","pubTimestamp":1747307890,"startTime":"0","endTime":"0","summary":"BUZZ-BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise ** BTIG starts coverage on Tvardi Therapeutics TVRD.O with \"buy\" rating and $55 PT, 108.7% upside to stock's last close** Brokerage says TVRD is \"presumptive first mover\" in developing STAT3 inhibitors for fibrotic diseases, targeting previously \"undruggable\" protein with \"highly validated and well-characterized\" profile** Fibrotic diseases are type of lung illnesses** Co's lead drug, TTI-101, has potential to be \"breakthrough therapy\" that can actually reverse these diseases, rather than just slowing their progression, BTIG says** Says early results from clinical trial are \"unusually persuasive\", with over 50% of patients showing improvement - outcome that is \"unlikely without an active therapy\"** Upcoming mid-stage trial data expected in 2H25 could be major catalyst for stock, BTIG says** As of last close, stock up 43.5% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nL4N3RN0XG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2535608296","title":"Tvardi Therapeutics Completes Merger with Cara Therapeutics, Secures Funding Through 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2535608296","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535608296?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:27","pubTimestamp":1747168062,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc., a clinical-stage biopharmaceutical company, has successfully completed its merger with Cara Therapeutics. As a result of the transaction, Tvardi received approximately $23.8 million in net cash from Cara, enhancing its financial position. This merger, combined with a previous private placement financing of $28.3 million, strengthens Tvardi's capability to fund its operations. The company now anticipates having sufficient resources to sustain its activities into the second half of 2026. The merger is expected to heighten Tvardi's visibility and access to capital, propelling its development programs, including those targeting idiopathic pulmonary fibrosis and hepatocellular carcinoma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDLbd06Bh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD","CARA"],"gpt_icon":0},{"id":"2535084673","title":"BRIEF-Tvardi Therapeutics Announces First Quarter 2025 Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535084673","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535084673?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:10","pubTimestamp":1747167006,"startTime":"0","endTime":"0","summary":"BRIEF-Tvardi Therapeutics Announces First Quarter 2025 Results And Provides Business UpdateMay 13 (Reuters) - Tvardi Therapeutics Inc TVRD.O:TVARDI THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 RESULTS AN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA30Z4VF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2535812740","title":"Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535812740","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535812740?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA30Z4VF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"2535532084","title":"Tvardi Therapeutics Inc - Completes Merger With Cara Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2535532084","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535532084?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA30Z4VF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2535084536","title":"Tvardi Therapeutics: on Track for Multiple Phase 2 Data Readouts With Stat3 Inhibitor, Tti-101, With Lead Program in Ipf Expected in 2H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2535084536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535084536?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA30Z4VF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVRD","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"TVRD","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-3.22},{"market":"US","date":"2025-04-16","symbol":"TVRD","defaultRemindTime":1744810200000,"type":"split","dateTimestamp":1744776000000,"forFactor":3,"toFactor":1,"ratio":3},{"market":"US","date":"2025-03-11","symbol":"TVRD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-12-31","symbol":"TVRD","defaultRemindTime":1735655400000,"type":"split","dateTimestamp":1735621200000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2024-11-14","symbol":"TVRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1749787200000}}}